Pembro Plus CAR T-cell Therapy in R/R in PMBCL

Pembrolizumab via iv, dosage and timing per protocol

Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC

Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.

manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier